使用Kendall's τ量化肿瘤试验中无进展生存期与总生存期的关联
本文综述了肿瘤试验中无进展生存期与总生存期关联的估计方法,包括Copula模型、非参数方法和疾病-死亡模型。通过模拟研究和结肠癌临床试验数据验证,疾病-死亡模型方法在多种场景下能提供良好的Kendall's τ估计,而Copula方法性能依赖Copula选择且实际应用存疑。
要点
- 疾病-死亡模型方法在多种场景下对Kendall's τ估计表现良好。
- Copula方法性能对Copula选择敏感,实际应用存疑。
- Clayton Copula在反映肿瘤试验的场景中最合适。
核心结论
- 疾病-死亡模型方法能提供良好的Kendall's τ估计。
- Copula方法性能敏感于Copula选择,实践应用存疑。
研究设计与样本
- 方法学综述与模拟研究,并使用结肠癌治疗临床试验数据。
主要发现
- 模拟显示疾病-死亡模型方法在多种场景下估计Kendall's τ良好。
- 某些情况下Copula方法表现良好但性能敏感于Copula选择。
- Clayton Copula在可能真实反映肿瘤试验的场景中最合适。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This paper considers methods for estimating the association between progression-free and overall survival in oncology trials. Copula-based, nonparametric, and illness-death model-based methods are reviewed. In addition, the approach based on an underlying illness-death model is generalized to allow general parametric models. The performance of these methods, in terms of bias and efficiency, is investigated through simulation and also illustrated using data from a clinical trial of treatments for colon cancer. The simulations suggest that the illness-death model-based method provides good estimates of Kendall's τ across several scenarios. In some situations, copula-based methods perform well but their performance is sensitive to the choice of copula. The Clayton copula is most appropriate in scenarios, which might realistically reflect an oncology trial, but the use of copula models in practice is questionable.
引用
- Weber EM, Titman AC. Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's τ. Stat Med. 2018. PMID: 30311243. doi:10.1002/sim.8001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。